Takeda Pharmaceutical Company Limited

Dyax Corporation

Jon A Kenniston

Andrew Nixon

Burt Adelman

Daniel J Sexton

Stephen R Comeau

Ryan Faucette

Christopher TenHoor

Gregory P Conley

Shauna Mason

Yung Chyung

Christopher Tenhoor

Kristopher Kopacz

Niksa Kastrapeli

Ryan Iarrobino

Joseph Biedenkapp

Allison P Lindberg

Greg Conley

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Assays for determining plasma kallikrein system biomarkers

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

Monoclonal antibody inhibitor of Factor XIIa

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.

Bispecific antibodies against plasma kallikrein and factor XII

Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

Anti-plasma kallikrein antibodies

Bispecific antibodies against plasma kallikrein and Factor XII

The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.

Methods of determining levels of cleaved and/or intact kininogen

Monoclonal antibody inhibitor of factor XIIA

Growing community of inventors

Hingham, MA, United States of America

Jon A Kenniston